Effects of miRNA-140 on the Growth and Clinical Prognosis of SMMC-7721 Hepatocellular Carcinoma Cell Line

Table 2

Cox regression analyses of factors predicting disease-free survival and overall survival of HCC.

Variable	DFS			OS
	HR	95% CI	value	HR	95% CI	value
Biological sex (female/male)	0.424	0.181-0.996	0.049	0.383	0.156-0.936	0.035
Age, years (<60/≥60)	0.394	0.161-0.966	0.042	0.327	0.130-0.822	0.017
Drinking history (no/yes)	0.963	0.371-2.504	0.939	1.355	0.533-3.441	0.523
Family history (no/yes)	1.529	0.569-4.109	0.400	1.473	0.526-4.127	0.461
BMI (≤25/>25)	1.047	0.375-2.923	0.930	0.811	0.297-2.22	0.684
AFP, ng/mL (<400/≥400)	1.771	0.814-3.853	0.149	1.286	0.605-2.734	0.514
Liver cirrhosis (no/yes)	0.604	0.269-1.357	0.222	0.589	0.263-1.321	0.199
Number of tumor (<3/≥3)	2.224	1.019-4.856	0.045	1.795	0.798-4.033	0.157
Metastasis (no/yes)	1.392	0.525-3.688	0.506	1.607	0.612-4.22	0.336
BCLC stage (0, A/B, C)	1.344	0.600-3.010	0.472	1.928	0.851-4.37	0.116
PVTT (no/yes)	2.519	0.824-7.697	0.105	1.468	0.487-4.429	0.496
miRNA-140expression (low/high)	0.357	0.175-0.726	0.004	0.42	0.210-0.837	0.014

Abbreviations: BMI: body mass index; AFP: alpha-fetoprotein; PVTT: portal vein tumor thrombus; BCLC stage: Barcelona Clinic Liver Cancer stage.